Pyxis Oncology (PYXS)
(Delayed Data from NSDQ)
$2.25 USD
-0.07 (-3.02%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $2.24 -0.01 (-0.44%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Pyxis Oncology, Inc. has a market cap of $143.88M, which represents its share price of $2.32 multiplied by its outstanding shares number of 62.02M. As a small-cap company, PYXS's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
PYXS 2.25 -0.07(-3.02%)
Will PYXS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PYXS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PYXS
Should You Buy Pyxis Oncology, Inc. (PYXS) After Golden Cross?
Investing in Oncology: 3 Cancer Stocks With Promising Pipelines
PYXS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
Other News for PYXS
The technical outlook for PYXS is unchanged after it falls 3.02% on September 19
PYXS forms Upper Bollinger Band Walk on September 18
Is PYXS building bullish momentum? Pocket Pivot shows up after rocketing 7.8%
Pyxis Oncology (PYXS) Gets a Buy from H.C. Wainwright
Golden Cross appears for PYXS after 7.89% move